Study of Elovie for advanced colorectal cancer
Part of Cancer, Digestive system clinical trials.
This study looks at how well a biosimilar version of bevacizumab (Elovie) works in people with advanced colorectal cancer that has spread and cannot be surgically removed. It aims to see if Elovie is safe and effective when used as the first treatment for this cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have been diagnosed with stage IV colorectal cancer that cannot be removed by surgery
- You are receiving your first treatment for this cancer, and you have either started with Elovie or switched to Elovie from another version of bevacizumab
- You have completed at least 1 cycle of Elovie and no more than 12 cycles total
- You do not have any other active cancer besides colorectal cancer
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug combination for people with colorectal cancer that has spread and cannot be removed by surgery. It compares the new drug plus standard chemotherapy against a placebo plus the same chemotherapy, to see if it helps shrink tumors and slow the disease.
This study tests a combination of two drugs (bevacizumab and adebrelimab) for people with a specific type of advanced colorectal cancer that has not responded to standard treatments. It aims to see if this combination can help control the cancer and improve outcomes.
This Phase 1 study tests targeted cancer treatments in people with metastatic colorectal cancer, using genetic “biomarker” results to match you to the right treatment group. It focuses first on safety, and also looks for early signs the treatment may work in specific tumor subgroups.
This study is testing a combination of drugs for colorectal cancer that has spread and hasn't responded to first-line treatment. It aims to see if these drugs can help control the cancer and improve outcomes for people in your situation.
This trial combines a new experimental drug (emavusertib) with standard chemotherapy (FOLFOX plus bevacizumab) for people with stage IV colorectal cancer who have not yet received chemotherapy. The goal is to see if the combination is safe and effective, potentially offering a new first-line treatment option.
This trial tests a new drug combined with a standard treatment for advanced colorectal cancer that has not responded to earlier therapies. It aims to see if the combination can help slow the cancer's growth.
Hear when a new Metastatic Colorectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.